嗜酸性蜂窝织炎中JAK2/STAT5通路过度激活及巴瑞替尼治疗评估
该病例系列研究分析14例嗜酸性蜂窝织炎患者和8名健康对照的皮肤活检样本,发现EC皮损存在显著2型炎症并优先激活JAK1/JAK2-STAT5通路;1例难治性EC患者口服巴瑞替尼4 mg/d 1个月后皮损完全临床缓解,提示EC是2型炎症性疾病且靶向JAK1/JAK2治疗具潜在价值。
要点
- EC皮损显示显著2型炎症(CCL17、CCL18、CCL26及IL-13)并优先激活JAK1/JAK2-STAT5通路。
- 1例难治性EC患者口服巴瑞替尼4 mg/d 1个月后皮损完全临床缓解。
- 结果提示EC是2型炎症性疾病,靶向JAK1/JAK2治疗对EC患者具潜在价值。
核心结论
- EC是2型炎症性疾病,皮损优先激活JAK1/JAK2-STAT5通路。
- 靶向JAK1/JAK2的治疗对EC患者具潜在价值。
研究设计与样本
- 纳入14例EC患者(男7例、女7例)和8名健康对照(男4例、女4例)的档案皮肤活检样本。
- 采用组织学、JAK-STAT免疫组化及基因表达谱分析。
主要发现
- EC患者平均(SD)年龄为52(20)岁。
- EC皮损中观察到显著2型炎症(趋化因子CCL17、CCL18、CCL26及IL-13)并优先激活JAK1/JAK2-STAT5通路。
- 1例难治性EC患者口服巴瑞替尼4 mg/d 1个月后皮损完全临床缓解。
关键数值与推荐
- 1例难治性EC患者口服JAK1/JAK2抑制剂巴瑞替尼4 mg/d。
- 评估指标包括瘙痒视觉模拟评分、皮损体表面积百分比及皮肤炎症生物标志物RNA转录本(阈值循环)。
临床怎么用
- EC皮损存在2型炎症及JAK1/JAK2-STAT5通路优先激活,支持靶向JAK1/JAK2的治疗探索。
- 1例难治性EC患者口服巴瑞替尼4 mg/d 1个月后达到皮损完全临床缓解。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The pathogenesis of eosinophilic cellulitis (EC) is poorly understood, limiting available treatment options. The current treatment paradigm focuses on delayed type 2 hypersensitivity reaction to various triggers. OBJECTIVE: To gain further insight into the nature of EC inflammation and into the cellular signal transduction pathways that are activated in the context of EC. DESIGN, SETTING, AND PARTICIPANTS: This case series was conducted in Lyon, France, from January 2018 to December 2021. Analysis of archival skin biopsy samples from patients with EC and from healthy control participants was performed using histology, Janus kinase (JAK)-signal transducer and activator of transcription (STAT) immunohistochemistry, and gene profiling. Data analysis was conducted between January 2020 and January 2022. MAIN OUTCOMES AND MEASURES: Pruritus (visual analog score), percentage of body surface area with lesional skin, and RNA transcripts of inflammatory biomarkers from the skin (threshold cycle) were assessed in 1 index patient with refractory EC who received oral JAK1/JAK2 inhibitor baricitinib (4 mg/d). RESULTS: This study included samples from 14 patients with EC (7 men and 7 women) and 8 healthy control participants (4 men and 4 women). The mean (SD) age of patients was 52 (20) years. Marked type 2 inflammation (chemokines CCL17, CCL18, and CCL26 and interleukin 13) with preferential activation of the JAK1/JAK2-STAT5 pathways in EC lesions was observed. In the 1 index patient with refractory EC, complete clinical remission of skin lesions was observed after 1 month of treatment with baricitinib. CONCLUSIONS AND RELEVANCE: These findings suggest that EC is a type 2 inflammatory disease with preferential activation of the JAK1/JAK2-STAT5 pathways. In addition, these results suggest the potential of treatment approaches targeting JAK1/JAK2 for patients with EC.
引用
- Morot J, Del Duca E, Chastagner M, et al. Hyperactivation of the JAK2/STAT5 Signaling Pathway and Evaluation of Baricitinib Treatment Among Patients With Eosinophilic Cellulitis. JAMA Dermatol. 2023. PMID: 37342057. doi:10.1001/jamadermatol.2023.1651
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。